Chris Picardo
Senior Associate @ Madrona
Seattle, United States
Chris Picardo is a Partner at Madrona Venture Group.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 86%
Last updated:
For AI agents: llms.txt
Industries Chris Picardo invests in
Stages Chris Picardo invests in
Countries Chris Picardo invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 4 (57%)
- Biopharma 2 (29%)
- InsurTech 2 (29%)
- Health Care 2 (29%)
- Therapeutics 2 (29%)
Stage
- Seed 3 (43%)
- Series A 2 (29%)
- Series B 1 (14%)
- Series C 1 (14%)
Country
- United States 5 (71%)
- Israel 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Faye provides whole-trip travel coverage and care that brings out the best in each journey with industry-leading technology that enables smarter, faster, smoother assistance and claims resolutions. Our robust travel insurance covers your health, your trip, your stuff, and even your pet, via an app that provides real-time proactive solutions,quick reimbursements and 24/7 customer experience specialists who turn travel mishaps into laugh-about-it-later memories. Join our team of travel and insurance experts as we set a new standard by overdelivering in an industry oftentimes synonymous with doing the opposite. | $50M / Series C / Aug 05, 2026 | ||
| Anzen is a management insurance and operations tool using real-time HRIS and SaaS integrations to identify and avoid management risks. The company was founded in 2020 and is headquartered in San Francisco, California, United States. | $16M / Series A / Nov 13, 2025 | ||
| Aizen is an AI-driven biotechnology company that is pioneering the development of Mirror Peptides, a novel class of biologic medicines. | $13M / Seed / Nov 21, 2024 | ||
| Archon is a biotechnology firm that creates computationally engineered proteins to unleash potent therapeutic targets beyond the grasp of current methods and improve disease management. | $20M / Seed / Oct 30, 2024 | ||
| Terray Therapeutics is a biotechnology company that integrates experimentation and computation to enhance small molecule drug discovery. The platform generates extensive, precise data through a rapid design-make-test-analyze cycle, allowing for efficient exploration of chemical space. By focusing on both wet lab science and AI, the companyaddresses complex therapeutic challenges across various targets. | $120M / Series B / Oct 17, 2024 | ||
| Terray Therapeutics is a biotechnology company that integrates experimentation and computation to enhance small molecule drug discovery. The platform generates extensive, precise data through a rapid design-make-test-analyze cycle, allowing for efficient exploration of chemical space. By focusing on both wet lab science and AI, the companyaddresses complex therapeutic challenges across various targets. | $60M / Series A / Feb 15, 2022 | ||
| Modulus Therapeutics is an artificial-intelligence-powered cell therapy design company. | $3.5M / Seed / Jul 15, 2021 |
Co-Investors
About Madrona
Madrona Venture Group is a Seattle-based venture capital firm. The firm prefers to invest in businesses that are involved in information technology, e-commerce, digital media, advertising, software, gaming, data, analytics, mobile, and infrastructure.
Madrona Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Chris Picardo
Senior Associate
|
|||
Hope Cochran
Managing Director
|
|||
John Torrey
Venture Partner
|
|||
Jon Turow
Partner
|
|||
Len Jordan
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Chris Picardo invest in?
Chris Picardo invests primarily in Biotechnology, Biopharma and InsurTech startups, most often at Seed and Series A stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Chris Picardo?
Public channels for Chris Picardo include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Chris Picardo last invest?
The most recent investment recorded for Chris Picardo closed in Aug 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
